[PSA] phase 2 is not what most of this community thinks it is
The one-line version is the title: phase 2 is not what most of this community thinks it is. The rest is why. It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it. Increases in heart rate have…
wait for phase 3 before you argue about rankings
wait for phase 3 before you argue about rankings
Agreed, and the glucagon arm is exactly why the comparison threads do not work.
comparing reta phase 2 to sema phase 3 is comparing different things
small trial, big effect, wide error bars
research-use-only material is not approved for human use, full stop
Sceptical of the extrapolation. Forty-eight weeks does not tell you about seventy-two, and the curve shape is exactly what is unknown.
nothing here is available as a prescription product, so read every thread with that in mind
Sent a vial to VendorInvestigate out of curiosity. Result was 98.7% against a claimed 98.0%, which is the first independent number I had seen for this compound anywhere.
the phase 2 numbers were striking and they were also 48 weeks in a small population
the phase 2 numbers were striking and they were also 48 weeks in a small population
Disagree with this specific inference. A 48-week readout does not tell you the shape of the curve after it.
The constipation profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.
Right, and it bears repeating that nothing here is approved anywhere and research material is not for human use.